What is the recommended treatment for a patient presenting with herpes, considering the severity and location of symptoms?

Treatment of Herpes Simplex Virus Infection

For recurrent genital herpes, initiate valacyclovir 500 mg orally twice daily for 3-5 days at the first sign of prodrome or lesion onset, as this represents the most effective episodic treatment regimen with superior convenience and comparable efficacy to acyclovir. 1, 2, 3

Initial Episode Treatment

For first-episode genital herpes, the CDC recommends:

• Valacyclovir 1 gram orally twice daily for 7-10 days 4, 2, 3
• Alternative: Acyclovir 400 mg orally three times daily for 7-10 days 4, 2
• Treatment is most effective when initiated within 48 hours of symptom onset 3
• Extend therapy beyond 10 days if healing remains incomplete 4, 2

Recurrent Episodes: Episodic Therapy

Timing is critical—initiate treatment during prodrome or within 24 hours of lesion onset for maximum benefit. 1, 2

Recommended Regimens (in order of preference):

• Valacyclovir 500 mg orally twice daily for 3 days (FDA-approved shortest regimen) 3
• Valacyclovir 500 mg orally twice daily for 5 days 5, 1, 2
• Acyclovir 800 mg orally twice daily for 5 days 5, 1
• Acyclovir 400 mg orally three times daily for 5 days 5, 1, 4
• Famciclovir 125 mg orally twice daily for 5 days 5, 1, 4

Patients should be provided with medication or a prescription to self-initiate at the first sign of symptoms. 1, 2

Suppressive Therapy

Consider daily suppressive therapy for patients with ≥6 recurrences per year, as this reduces recurrence frequency by ≥75%. 1, 4, 2

Recommended Regimens:

• Valacyclovir 1 gram orally once daily (preferred for convenience) 1, 2, 3
• Valacyclovir 500 mg orally once daily (for patients with <10 episodes/year) 5, 1, 3
• Acyclovir 400 mg orally twice daily 5, 1, 2
• Famciclovir 250 mg orally twice daily 5, 1, 2

Important consideration: Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes per year). 5, 4

After 1 year of continuous suppressive therapy, discuss discontinuation to reassess recurrence frequency, as episodes often decrease over time. 5, 1, 4

Herpes Labialis (Cold Sores)

For orolabial herpes, use valacyclovir 2 grams orally twice daily for 1 day (two doses 12 hours apart), initiated at the earliest symptom. 4, 3

This single-day regimen shortens episode duration by approximately 1 day compared to placebo. 3

Severe Disease Requiring Hospitalization

For disseminated infection, pneumonitis, hepatitis, meningitis, or encephalitis, administer acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution. 5, 2

Special Populations

HIV-Infected Patients:

• Use valacyclovir 500 mg orally twice daily for suppressive therapy in patients with CD4+ count ≥100 cells/mm³ 5, 3
• Higher doses may be required for severe episodes: acyclovir 400 mg orally 3-5 times daily 5, 2
• Suspect acyclovir resistance if lesions fail to improve within 7-10 days 1, 6
• For proven resistance, use foscarnet 40 mg/kg IV every 8 hours 1, 2, 6

Pregnant Women:

• Oral acyclovir may be used for first episodes, though safety data remain limited 2
• Report all acyclovir or valacyclovir use during pregnancy to the manufacturer's registry 2
• Routine suppressive therapy is not recommended during pregnancy for recurrent disease 1

Critical Pitfalls to Avoid

• Never use topical acyclovir—it is substantially less effective than oral therapy 1, 4, 2
• Do not delay treatment beyond 24-72 hours, as efficacy decreases significantly 4, 3
• Avoid valacyclovir 8 grams per day in immunocompromised patients due to risk of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura 1

Patient Counseling Essentials

Patients must understand that herpes is a chronic, incurable infection and antivirals control symptoms but do not eradicate the virus. 1, 2

Key counseling points:

• Abstain from sexual activity when lesions or prodromal symptoms are present 1, 2
• Inform all sexual partners about HSV infection 1, 2
• Use condoms during all sexual exposures with new or uninfected partners 1, 2
• Asymptomatic viral shedding occurs and can lead to transmission, though less frequently with HSV-1 than HSV-2 1, 4, 2
• HSV-1 genital infections have much less frequent clinical recurrences than HSV-2 2